PU-H71 HCl

Product Specifications

CAS Number

2095432-24-7

Target

HSP|||DNA/RNA Synthesis

Related Pathways

Cytoskeletal Signaling|||DNA Damage/DNA Repair|||Metabolism|||Cell Cycle/Checkpoint

Purity

0.9945

Bioactivity

PU-H71 HCl (Zelavespib HCl) is a novel Hsp90 inhibitor, a novel purine-based analog, and a radiosensitizer that may be a promising agent for CIRT. PU-H71 HCL shows antitumor activity in many preclinical models of malignancy. PU-H71 HCL has an inhibitory effect on the protein expression levels of Rad51 and Ku70, which may be associated with the double chain break repair in the homologous recombination pathway and non-homologous end-joining pathway.